December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Bladder-sparing Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer
Dec 24, 2024, 23:31

Bladder-sparing Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer

A recent paper by Roger Li, Urologic oncologist at Moffitt Cancer Center, was mentioned by Enrique Grande, Associate Professor at Francisco de Vitoria University, on X:

“Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.”

Authors: Roger Li, Patrick Hensley, Shilpa Gupta, Roger Buckley, Ashish Kamat et al.

Bladder-sparing Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer

More posts featuring Enrique Grande.

Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center.

Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.

He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.

Dr. Roger Li is a urologic oncologist at Moffitt Cancer Center, specializing in the surgical treatment of bladder, prostate, kidney, and penile cancers. He offers open, laparoscopic, and robotic-assisted procedures, including nerve-sparing options.

Dr. Li received advanced training in urologic oncology at MD Anderson Cancer Center. Dr. Li researches personalized therapies through genomic profiling and develops new immunotherapies for early-stage bladder cancer.